EP4698631A1 - Cellules et cultures cellulaires améliorées - Google Patents

Cellules et cultures cellulaires améliorées

Info

Publication number
EP4698631A1
EP4698631A1 EP24722742.4A EP24722742A EP4698631A1 EP 4698631 A1 EP4698631 A1 EP 4698631A1 EP 24722742 A EP24722742 A EP 24722742A EP 4698631 A1 EP4698631 A1 EP 4698631A1
Authority
EP
European Patent Office
Prior art keywords
fold
cell
txnip
cells
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24722742.4A
Other languages
German (de)
English (en)
Inventor
Shelby Hutchins BREEN
Bhanu Chandra MULUKUTLA
Madeline Hoft RAFA
John Joseph SCARCELLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of EP4698631A1 publication Critical patent/EP4698631A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des cellules présentant une croissance améliorée et des cultures cellulaires associées. Selon certains aspects, les cellules de l'invention présentent une expression accrue de la protéine interagissant avec la thiorédoxine (TXNIP).
EP24722742.4A 2023-04-21 2024-04-18 Cellules et cultures cellulaires améliorées Pending EP4698631A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363497460P 2023-04-21 2023-04-21
US202463575398P 2024-04-05 2024-04-05
PCT/IB2024/053791 WO2024218706A1 (fr) 2023-04-21 2024-04-18 Cellules et cultures cellulaires améliorées

Publications (1)

Publication Number Publication Date
EP4698631A1 true EP4698631A1 (fr) 2026-02-25

Family

ID=90924006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24722742.4A Pending EP4698631A1 (fr) 2023-04-21 2024-04-18 Cellules et cultures cellulaires améliorées

Country Status (2)

Country Link
EP (1) EP4698631A1 (fr)
WO (1) WO2024218706A1 (fr)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
US7429491B2 (en) 2003-05-15 2008-09-30 Wyeth Restricted glucose feed for animal cell culture
US20220118107A1 (en) * 2019-02-11 2022-04-21 President And Fellows Of Harvard College Txnip and ldhb compositions and methods for the treatment of degenerative ocular diseases

Also Published As

Publication number Publication date
WO2024218706A1 (fr) 2024-10-24

Similar Documents

Publication Publication Date Title
US10870856B2 (en) RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
US20250051779A1 (en) Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
KR101114741B1 (ko) 알파-1,6-푸코실 전이효소 발현의 ｓｈｒｎａ-조절된 억제
JP2013136624A (ja) 脱髄の関与する状態の処置
US20110251256A1 (en) Use of trim72 as a target for muscle and heart enhancer
KR20220116520A (ko) 파타틴-유사 포스포리파제 도메인 함유 3 (PNPLA3) iRNA 조성물 및 이의 사용 방법
KR20180117189A (ko) 세포 배양 공정
KR101638156B1 (ko) C형 간염 바이러스 감염 질환의 예방 또는 치료용 약학 조성물
KR20180128443A (ko) 분비형 단백질을 생산하기 위한 포유동물 세포
CN101903529A (zh) 基于sm-蛋白的分泌工程化
AU2012324495B2 (en) Addition of iron to improve cell culture
WO2024218706A1 (fr) Cellules et cultures cellulaires améliorées
JP2023500116A (ja) ｃｏｎ－希少コドンのためのＴＲＥＭ組成物及び関連する使用
DK2339015T3 (en) Methods for changing protein production rates
JP4762133B2 (ja) Ｗｔ１遺伝子の発現を抑制するマイクロｒｎａおよびその利用
EP2471918A1 (fr) Méthode de criblage
US20110092575A1 (en) Sirna of human osteopontin
US20240254484A1 (en) SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION FACTOR 6 (STAT6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA2621326A1 (fr) Activateur membranaire conserve de la calcineurine ("conserved membrane activator of calcineurin" ou cmac), nouvelle proteine et cible therapeutique
JP7325075B2 (ja) フリズルド３発現細胞の細胞数増加剤若しくは低下剤、糖尿病予防若しくは治療剤、インスリノーマ予防若しくは治療剤、及びインスリン分泌促進剤若しくは分泌抑制剤よりなる群から選択される少なくとも１つの剤をスクリーニングするためのスクリーニング剤、スクリーニング用キット、及びスクリーニング方法
JPWO2008105498A1 (ja) Ｉｌ−１７に起因する炎症を改善するための医薬組成物
WO2008079705A2 (fr) Acyl-transférase
US20160361391A1 (en) Reduction of traf1 levels combined with nutrient stress for treating lymphocyte-related cancers
EP2331135A1 (fr) Procédés de traitement et de prévention de la toxicité du glucose
MX2008004412A (en) Conserved membrane activator of calcineurin (cmac), a novel therapeutic protein and target

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR